Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
=== Chemical and molecular properties === A neutral atom has the same number of electrons as protons. Thus different isotopes of a given element all have the same number of electrons and share a similar electronic structure. Because the chemical behaviour of an atom is largely determined by its electronic structure, different isotopes exhibit nearly identical chemical behaviour. The main exception to this is the kinetic isotope effect: due to their larger masses, heavier isotopes tend to react somewhat more slowly than lighter isotopes of the same element. This is most pronounced by far for protium (1H), deuterium (2H), and tritium (3H), because deuterium has twice the mass of protium and tritium has three times the mass of protium. These mass differences also affect the behavior of their respective chemical bonds, by changing the center of gravity (reduced mass) of the atomic systems. However, for heavier elements, the relative mass difference between isotopes is much less so that the mass-difference effects on chemistry are usually negligible. (Heavy elements also have relatively more neutrons than lighter elements, so the ratio of the nuclear mass to the collective electronic mass is slightly greater.) There is also an equilibrium isotope effect.
== Sports == F2 Logistics is also involved in sports. It formerly owned the F2 Logistics Cargo Movers, a women's volleyball team active from 2016 to 2023. It competed in the Philippine Super Liga and Premier Volleyball League. It also sponsors the La Salle women's volleyball team and the Parañaque Patriots basketball team of the Maharlika Pilipinas Basketball League.
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.
The Jameson Raid (Afrikaans: Jameson-inval, lit. ''Jameson's Invasion'', 29 December 1895 – 2 January 1896) was a botched raid against the South African Republic (commonly known as the Transvaal) carried out by British colonial administrator Leander Starr Jameson, under the employment of Cecil Rhodes. It involved 500 British South Africa Company police and was launched from Rhodesia over the New Year weekend of 1895–96. Paul Kruger, for whom Rhodes had great personal hatred, was president of the South African Republic at the time. The raid was intended to trigger an uprising by the primarily British expatriate and settler workers (known as Uitlanders) in the Transvaal, but it failed. The workers were referred to as the Johannesburg Conspirators. They were expected to recruit an army and prepare for an insurrection; however, the raid was ineffective, and no uprising took place. The results included embarrassment of the British government; the replacement of Cecil Rhodes as prime minister of the Cape Colony; and the strengthening of Boer dominance of the Transvaal and its gold mines. Also, the withdrawal of so many fighting men left Rhodesia vulnerable, one factor that led just a couple of months later to the Second Matabele War. The raid was a contributory cause of the Second Boer War.
Sources: en.wikipedia.org
==== Effect on the company and bankruptcy ==== The value of the company plunged as a result of the scandal. On 24 September, Fonterra announced it had written down the carrying value of its investment by NZ$139 million (two-thirds), reflecting the costs of product recall and the impairment of the 'Sanlu' brand because of the "criminal contamination of milk". By 27 September, China Daily reported Sanlu was close to bankruptcy, and might be taken over by the Beijing Sanyuan Foods Company. The company is also facing lawsuits from parents (see Anger at Sanlu). The Beijing Review said Sanlu expects to have to pay compensation claims totalling ¥700 million, and it became clear the company would be broken up and sold. On 25 December, Shijiazhuang court accepted a creditor's bankruptcy petition against Sanlu. Media commentators expected the Sanlu distribution network to be sold.
Once the cell has received a non-trivial load, and has expended the phosphocreatine reserve, a small quantity of ATP will become discharged down to AMP. AMP will instantly up-regulate myophosphorylase, which will start liberating glucose from glycogen and make it available to the glycolytic pathway, producing pyruvate and recharging AMP back to ATP. Due to the greater availability of pyruvate as a substrate, and pyruvate also contributing a citric acid cycle intermediate, α-ketoglutarate, while consuming glutamate, the citric acid cycle will also speed up. The combination of glycolysis and the citric acid cycle now balances ATP production with ATP demand and the pool of AMP does not grow further. Because all pyruvate is not burned down in the citric acid cycle—a consequence of the pyruvate's concentration regulating its burning at this moment—the excess is converted to lactate and passed into blood as lactic acid. In muscle cells with normal AMPD activity, the purine nucleotide cycle would now start to gradually add fumarate to the pool of the citric acid cycle intermediates. This would decrease the excess rate of pyruvate production by increasing its consumption, increase the rate of AMP recharge to ATP by the citric acid cycle, and consequently reduce liberation of glucose from glycogen, until increased supply of blood-borne fuels allows to shut down glycogenolysis completely. In muscle cells with AMPD deficiency, ATP production rate of the citric acid cycle will not be synchronized with ATP demand.
The Irish Free State (6 December 1922 – 29 December 1937), also known by its Irish name Saorstát Éireann, was the Irish state established in December 1922 under the Anglo-Irish Treaty of December 1921, initially as a Dominion. The treaty ended the three-year Irish War of Independence between the forces of the Irish Republic—the Irish Republican Army (IRA)—and British Crown forces. As per the 6 December 1922 Constitution of the Irish Free State, the new state was called the Irish Free State and became a Dominion of the British Empire. It comprised 26 of the 32 counties of Ireland. Northern Ireland, which was made up of the remaining six counties, exercised its right under the Treaty to opt out of the new state. The Free State government consisted of the governor-general—the representative of the king—and the Executive Council (cabinet), which replaced both the revolutionary Dáil Government and the Provisional Government set up under the Treaty. W. T. Cosgrave, who had led both of these administrations since August 1922, became the first president of the Executive Council (prime minister). The Oireachtas or legislature consisted of Dáil Éireann (the lower house) and Seanad Éireann (the upper house), also known as the Senate. Members of the Dáil were required to take an Oath of Allegiance to the Constitution of the Free State and to declare fidelity to the king. The oath was a key issue for opponents of the Treaty, who refused to take it and therefore did not take their seats.
Noncatalytic functions that FAD can play in flavoproteins include as structural roles, or involved in blue-sensitive light photoreceptors that regulate biological clocks and development, generation of light in bioluminescent bacteria.
=== Synthesis === Synthesis of RNA typically occurs in the cell nucleus and is usually catalyzed by an enzyme—RNA polymerase—using DNA as a template, a process known as transcription. Initiation of transcription begins with the binding of the enzyme to a promoter sequence in the DNA (usually found "upstream" of a gene). The DNA double helix is unwound by the helicase activity of the enzyme. The enzyme then progresses along the template strand in the 3' to 5' direction, synthesizing a complementary RNA molecule with elongation occurring in the 5' to 3' direction. The DNA sequence also dictates where termination of RNA synthesis will occur. Primary transcript RNAs are often modified by enzymes after transcription. For example, a poly(A) tail and a 5' cap are added to eukaryotic pre-mRNA and introns are removed by the spliceosome. There are also a number of RNA-dependent RNA polymerases that use RNA as their template for synthesis of a new strand of RNA. For instance, a number of RNA viruses (such as poliovirus) use this type of enzyme to replicate their genetic material. Also, RNA-dependent RNA polymerase is part of the RNA interference pathway in many organisms.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.